Medicare speeds payment for unproven devices, betting on innovation.
H.R. 4441 — Patient Access to Innovative New Technologies Act of 2025 · Filed by Mike Carey (R-OH) · 2 cosponsors · Introduced Jul 16, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill allows Medicare to pay hospitals extra money for using newly approved medical devices that the FDA has designated as 'breakthrough' innovations, even before those devices complete full FDA approval—as long as they receive some form of FDA clearance by July 1 of the fiscal year in question. The goal is to speed patient access to promising new medical technologies without waiting for the full approval process to finish.
Why we flagged it
The bill's operative mechanism is a conditional payment pathway for breakthrough devices under Medicare's New Technology Add-On Payment program. It is not a blanket deregulation but a targeted reimbursement rule change designed to incentivize adoption of FDA-designated innovations before full approval.
What the text implies
- Hospitals gain financial incentive to adopt devices with incomplete safety/efficacy data; the 'breakthrough' designation is an FDA expedited-review marker, not a completed safety finding.
- Budget-neutral language in clause (III) may be aspirational rather than binding; if devices are widely adopted, actual costs could exceed projections, pressuring Medicare finances.
The full analysis lists 5 implications of this text.
Who stands to gain
medical device manufacturers (breakthrough device makers); hospitals and health systems (add-on payment revenue); device distributors and suppliers